Detailed Information on Publication Record
2004
Galantamine added to olanzapine improves prefrontal cortex functioning in schizophrenia: a case fMRI study.
KAŠPÁREK, Tomáš, Radovan PŘIKRYL, Hana KUČEROVÁ, Petr KRUPA, Eva ČEŠKOVÁ et. al.Basic information
Original name
Galantamine added to olanzapine improves prefrontal cortex functioning in schizophrenia: a case fMRI study.
Name (in English)
Galantamine added to olanzapine improves prefrontal cortex functioning in schizophrenia: a case fMRI study.
Authors
KAŠPÁREK, Tomáš (203 Czech Republic, guarantor), Radovan PŘIKRYL (203 Czech Republic), Hana KUČEROVÁ (203 Czech Republic), Petr KRUPA (203 Czech Republic), Eva ČEŠKOVÁ (203 Czech Republic) and Michal MIKL (203 Czech Republic)
Edition
Psychiatrie, Praha, TIGIS, 2004, 1211-7579
Other information
Language
Czech
Type of outcome
Článek v odborném periodiku
Field of Study
30000 3. Medical and Health Sciences
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14110/04:00010311
Organization unit
Faculty of Medicine
Keywords in English
galantamine; schizophrenia; fMRI
Tags
Změněno: 23/9/2004 07:25, prof. MUDr. Tomáš Kašpárek, Ph.D.
V originále
Galantamin added to olanzapin in a patient with persistent cognitive dysfunction improved memory functions measured by WMS IIIR. Subtest "Faces" from WMS III was used as activation paradigm in fMRI. At baseline, there were almost no activation, after 4 weeks of galantamine treatment significant activity appeared in the prefrontal cortex.
In English
Galantamin added to olanzapin in a patient with persistent cognitive dysfunction improved memory functions measured by WMS IIIR. Subtest "Faces" from WMS III was used as activation paradigm in fMRI. At baseline, there were almost no activation, after 4 weeks of galantamine treatment significant activity appeared in the prefrontal cortex.
Links
| NF7028, research and development project |
|